Impact Therapeutics Entered into Global Partnership with Eikon Therapeutics to Develop and Commercialize PARP1 Selective Inhibitors
“We are delighted to establish the global partnership with Eikon, whose leadership team has a well-documented track record of developing some of the world’s most therapeutically meaningful and commercially successful oncology medicines.” said Sui Xiong Cai, Ph.D., Chief Executive Officer of IMPACT Therapeutics. “As a company committed to develop innovative medicines globally, based on our deep understanding of synthetic lethality, we believe this partnership will allow us to accelerate the development of our PARP1 selective inhibitor program combining Impact and Eikon’s scientific, clinical, regulatory expertise and financial resources. We look forward to working with Eikon in bringing new cancer medicines to patients in China and across the globe.”
Share:
More News
“Between 2017 and 2023, the socioeconomic burden of HER2-positive breast cancer in ten major economies was nearly $590 billion, projected to increase to nearly $1,000 billion by 2032,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product Development. “At-home treatment may help alleviate the pressure
Richard Saynor, CEO of Sandoz, said: “The global burden of cancer continues to grow and the potential to address unmet patient needs has never been greater. This agreement offers us the chance to reach many more millions of patients, while helping to drive the long-term sustainability of healthcare systems.”
“Beyond the second-line monotherapy opportunity, we and our partners at Pfizer have removed plans for a Phase 3 first-line combination trial with atirmociclib, as well as the planned Phase 3 second-line combination trial with a CDK4/6 inhibitor, from our joint development plan,” continued Dr. Houston. “This decision was made following
“The interim PFS analysis results demonstrated that, compared to the current standard treatment, KN026 in combination with chemotherapy significantly improved PFS, reduced the risk of disease progression or death, and showed a trend toward OS benefit. Detailed data from this study will be presented at an upcoming international academic conference.”
